Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kodiak Sciences ( (KOD) ) just unveiled an update.
On March 26, 2026, Kodiak Sciences reported positive topline results from GLOW2, its second Phase 3 trial in diabetic retinopathy, where Zenkuda given on a six-month dosing interval showed clear superiority to sham. In the 48-week study, 62.5% of Zenkuda-treated patients achieved at least a two-step improvement in diabetic retinopathy severity versus 3.3% on sham, and the therapy cut the risk of sight-threatening complications by 85% while delivering favorable safety outcomes.
The trial extended the earlier GLOW1 findings to a broader, higher-risk population including proliferative diabetic retinopathy and mild diabetic macular edema, and demonstrated consistent efficacy regardless of patients’ concomitant GLP-1 use. With GLOW2 validating strong efficacy, durability, and safety using its enhanced commercial formulation, Kodiak now views Zenkuda as having a multi-indication, BLA-ready profile and sees supportive read-through for its broader ABC-based pipeline, potentially strengthening its competitive position in retinal therapeutics.
The most recent analyst rating on (KOD) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Kodiak Sciences stock, see the KOD Stock Forecast page.
Spark’s Take on KOD Stock
According to Spark, TipRanks’ AI Analyst, KOD is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, sizable losses/cash burn, and recently higher leverage), partially offset by strong technical momentum and a liquidity-positive capital raise. Valuation provides limited support given the negative P/E and no dividend yield data.
To see Spark’s full report on KOD stock, click here.
More about Kodiak Sciences
Kodiak Sciences Inc. is a precommercial, retina-focused biotechnology company listed on Nasdaq that develops intravitreal biologic therapies for retinal vascular diseases. Its lead candidate, Zenkuda (tarcocimab tedromer), is an anti-VEGF biologic built on the company’s proprietary Antibody Biopolymer Conjugate platform, targeting diabetic retinopathy and other sight-threatening eye conditions.
Average Trading Volume: 927,123
Technical Sentiment Signal: Buy
Current Market Cap: $2.43B
See more insights into KOD stock on TipRanks’ Stock Analysis page.